Full Prescribing Information Important Safety Information
Print Go to APONVIE.com

Heron Connect®—
We've got it covered

Heron Connect provides support services that meet the needs of providers. Our access solutions are designed to assist with questions related to billing and coding, payer coverage, benefit verification, drug returns, and more.

Heron Connect services provide the access solutions you need*

  • Dedicated Reimbursement Counselors: Your counselor will be a single point of contact to ensure that you have the necessary information to appropriately bill and code APONVIE®.
    • Provide up-to-date information on CMS policies and payment rates as well as commercial payer guidelines
    • Provide product-specific coding details and assistance with claims submission and issue resolution
    • Help confirm payer coverage details and get payer information by site of care
  • Prior Authorization and Appeals Support
  • Drug Replacement: In the event that the APONVIE 10-unit box is damaged during shipment or the product has expired, Heron Therapeutics, Inc., will provide a replacement. Call Heron Connect for more information at 1-844-HERON11 (1-844-437-6611)†
  • Product Information: Call if you have a clinical inquiry or would like to report an adverse event related to aponvie

For more information on Heron Connect, call 1-844-HERON11 (1-844-437-6611) from 8:30 am to 5 pm ET, Monday through Friday.

  1. Heron Therapeutics, Inc., reserves the right, at its sole discretion, to change the qualifications of Heron Connect at any time. Product support programs offered by Heron Therapeutics, Inc., do not impose any purchase obligation at any time or in any manner. Use of APONVIE may be discontinued at any time, without penalty.
  2. Determination will be made by the manufacturer of APONVIE.

toggle

INDICATION

APONVIE is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.

Limitations of Use: APONVIE has not been studied for treatment of established nausea and vomiting.

IMPORTANT SAFETY INFORMATION

Contraindications

APONVIE is contraindicated in patients with a history of hypersensitivity to aprepitant or any component of the product, and in patients taking pimozide. Increased pimozide levels may cause serious or life-threatening reactions, such as QT prolongation.

Warnings and Precautions

Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, during or soon after administration of aprepitant have occurred. Symptoms including dyspnea, eye swelling, flushing, pruritus, and wheezing have been reported. Monitor patients during and after administration. If hypersensitivity reactions occur, administer appropriate medical therapy. Do not administer APONVIE in patients who experienced these symptoms with previous use of aprepitant.

Clinically Significant CYP3A4 Drug Interactions: Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. Use of pimozide, a CYP3A4 substrate, with APONVIE is contraindicated. Use of APONVIE with strong CYP3A4 inhibitors (eg, ketoconazole) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to APONVIE. Use of APONVIE with strong CYP3A4 inducers (eg, rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of APONVIE.

Decrease in INR with Concomitant Warfarin: Use of aprepitant with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the International Normalized Ratio (INR) of prothrombin time. Monitor the INR in patients on chronic warfarin therapy in the 2-week period particularly at 7 to 10 days, following administration of APONVIE.

Risk of Reduced Efficacy of Hormonal Contraceptives: The efficacy of hormonal contraceptives may be reduced for 28 days following administration of APONVIE. Advise patients to use effective alternative or back-up methods of non-hormonal contraception for 1 month following administration of APONVIE.

Use in Specific Populations

Avoid use of APONVIE in pregnant women as alcohol is an inactive ingredient in APONVIE. There is no safe level of alcohol exposure in pregnancy.

Adverse Reactions

Most common adverse reactions (incidence ≥3%) for APONVIE are constipation, fatigue, and headache and for oral aprepitant are constipation and hypotension.

Report side effects to Heron at 1-844-437-6611 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For more information about APONVIE, please see full Prescribing Information, or visit www.APONVIE.com.